Valuation: Omeros Corporation

Market Cap 744M 651M 600M 554M 1.05B 70.96B 1.07B 7.17B 2.82B 34.96B 2.79B 2.73B 120B P/E 2026 *
31.2x
P/E 2027 * -36.7x
Enterprise Value 744M 651M 600M 554M 1.05B 70.96B 1.07B 7.17B 2.82B 34.96B 2.79B 2.73B 120B EV / Sales 2026 *
11x
EV / Sales 2027 * 5.2x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+0.10%
1 week+10.78%
Current month+8.10%
1 month+0.78%
3 months-10.53%
6 months-17.69%
Current year-40.15%
1 week 9.25
Extreme 9.25
10.68
1 month 6.7
Extreme 6.7023
10.83
Current year 6.7
Extreme 6.7023
17.63
1 year 3.34
Extreme 3.34
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 16/06/1994
Director of Finance/CFO 62 30/06/2024
Chief Tech/Sci/R&D Officer 70 01/11/2019
Director TitleAgeSince
Chairman 67 16/06/1994
Director/Board Member 86 01/01/1995
Director/Board Member 72 01/01/1995
Date Insider Type Main position Quantity % Market Cap.
06-18Free

Director

15,000 0.0207%
06-18Free

Director

15,000 0.0207%
06-18Free

Director

15,000 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%+10.78%+197.11%+90.02% 744M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.60%+0.83%+68.59%+142.16% 24.19B
Weighted average by Cap. -0.91%-1.42%+55.48%+137.63%

Financials

2026 *2027 *
Net sales 67.83M 59.33M 54.73M 50.55M 95.91M 6.47B 97.52M 654M 257M 3.19B 255M 249M 10.96B 143M 125M 115M 107M 202M 13.65B 206M 1.38B 542M 6.72B 537M 526M 23.11B
Net income 21.23M 18.57M 17.13M 15.82M 30.02M 2.03B 30.53M 205M 80.38M 998M 79.72M 77.99M 3.43B -47.25M -41.33M -38.12M -35.21M -66.81M -4.51B -67.93M -455M -179M -2.22B -177M -174M -7.63B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
10/07/26 US$10.28 +0.10% 1,090,362
09/07/26 US$10.27 +0.29% 875,884
08/07/26 US$10.24 -0.87% 1,496,609
07/07/26 US$10.33 -0.10% 1,236,226
06/07/26 US$10.34 +11.42% 1,745,449
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
10.28USD
Average target price
33.00USD
Spread / Average Target
+221.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock